Radiotherapy & Oncology
Volume 94, Issue 1 , Pages 82-89 , January 2010

Endogenous and radiation-induced expression of γH2AX in biopsies from patients treated for carcinoma of the uterine cervix

  • Peggy L. Olive

      Affiliations

    • British Columbia Cancer Agency Research Centre, Vancouver, Canada
    • Corresponding Author InformationCorresponding author. Address: Medical Biophysics Department, British Columbia Cancer Agency Research Centre, 675 W. 10th Ave., Vancouver, BC, Canada V5Z 1L3.
    • ,
  • C. Adriana Banuelos

      Affiliations

    • British Columbia Cancer Agency Research Centre, Vancouver, Canada
    • ,
  • Ralph E. Durand

      Affiliations

    • British Columbia Cancer Agency Research Centre, Vancouver, Canada
    • ,
  • Joo-Young Kim

      Affiliations

    • National Cancer Center, Seoul, South Korea
    • ,
  • Christina Aquino-Parsons

      Affiliations

    • British Columbia Cancer Agency, Vancouver Clinic, Vancouver, Canada

Received 15 July 2009 ,Revised 1 October 2009 ,Accepted 14 October 2009.

References 

  1. Amundson SA, Do KT, Vinikoor LC, et al. Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res. 2008;68:415–424
  2. Banath JP, MacPhail SH, Olive PL. Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines. Cancer Res. 2004;64:7144–7149
  3. Banuelos CA, Banath JP, Kim JY, Aquino-Parsons C, Olive PL. γH2AX expression in tumors exposed to cisplatin and fractionated irradiation. Clin Cancer Res. 2009;15:3344–3353
  4. Bennewith KL, Durand RE. Quantifying transient hypoxia in human tumor xenografts by flow cytometry. Cancer Res. 2004;64:6183–6189
  5. Bentzen SM. From cellular to high-throughput predictive assays in radiation oncology: challenges and opportunities. Semin Radiat Oncol. 2008;18:75–88
  6. Bonner WM, Redon CE, Dickey JS, et al. GammaH2AX and cancer. Nat Rev Cancer. 2008;8:957–967
  7. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer. 2008;8:180–192
  8. Durand RE, Aquino-Parsons C. The fate of hypoxic (pimonidazole-labelled) cells in human cervix tumours undergoing chemo-radiotherapy. Radiother Oncol. 2006;80:138–142
  9. Economopoulou M, Langer HF, Celeste A, et al. Histone H2AX is integral to hypoxia-driven neovascularization. Nat Med. 2009;15:553–558
  10. Hammond EM, Kaufmann MR, Giaccia AJ. Oxygen sensing and the DNA-damage response. Curr Opin Cell Biol. 2007;19:680–684
  11. Iakovlev VV, Pintilie M, Morrison A, Fyles AW, Hill RP, Hedley DW. Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX. Lab Invest. 2007;87:1206–1217
  12. Jankovic B, Aquino-Parsons C, Raleigh JA, et al. Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix. Cytometry B Clin Cytom. 2006;70:45–55
  13. Kato TA, Nagasawa H, Weil MM, Little JB, Bedford JS. Levels of gamma-H2AX Foci after low-dose-rate irradiation reveal a DNA DSB rejoining defect in cells from human ATM heterozygotes in two at families and in another apparently normal individual. Radiat Res. 2006;166:443–453
  14. Kim JY, Cho HY, Lee KC, et al. Tumor apoptosis in cervical cancer: its role as a prognostic factor in 42 radiotherapy patients. Int J Cancer. 2001;96:305–312
  15. Klokov D, Macphail SM, Banath JP, Byrne JP, Olive PL. Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays. Radiother Oncol. 2006;80:223–229
  16. Kokkonen N, Ulibarri IF, Kauppila A, et al. Hypoxia upregulates carcinoembryonic antigen expression in cancer cells. Int J Cancer. 2007;121:2443–2450
  17. Lobrich M, Kiefer J. Assessing the likelihood of severe side effects in radiotherapy. Int J Cancer. 2006;118:2652–2656
  18. Lord CJ, Ashworth A. Bringing DNA repair in tumors into focus. Clin Cancer Res. 2009;15:3241–3243
  19. MacPhail SH, Banath JP, Yu TY, Chu EH, Lambur H, Olive PL. Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays. Int J Radiat Biol. 2003;79:351–358
  20. Mahrhofer H, Burger S, Oppitz U, Flentje M, Djuzenova CS. Radiation induced DNA damage and damage repair in human tumor and fibroblast cell lines assessed by histone H2AX phosphorylation. Int J Radiat Oncol Biol Phys. 2006;64:573–580
  21. Olive PL, Aquino-Parsons C, MacPhail SH, et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res. 2001;61:8924–8929
  22. Papandreou I, Krishna C, Kaper F, Cai D, Giaccia AJ, Denko NC. Anoxia is necessary for tumor cell toxicity caused by a low-oxygen environment. Cancer Res. 2005;65:3171–3178
  23. Porcedda P, Turinetto V, Orlando L, et al. Two-tier analysis of histone H2AX phosphorylation allows the identification of Ataxia Telangiectasia heterozygotes. Radiother Oncol. 2009;92:133–137
  24. Rankin EB, Giaccia AJ, Hammond EM. Bringing H2AX into the angiogenesis family. Cancer Cell. 2009;15:459–461
  25. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute’s Anticancer Drug Screen panel. Biochem Pharmacol. 1996;52:1855–1865
  26. Rogakou EP, Boon C, Redon C, Bonner WM. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol. 1999;146:905–916
  27. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273:5858–5868
  28. Rothkamm K, Kruger I, Thompson LH, Lobrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol. 2003;23:5706–5715
  29. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P. Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res. 2005;65:7259–7266
  30. Srivastava N, Gochhait S, de BP, Bamezai RN. Role of H2AX in DNA damage response and human cancers. Mutat Res. 2009;682:180–188
  31. Taneja N, Davis M, Choy JS, et al. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem. 2004;279:2273–2280
  32. Troost EG, Bussink J, Kaanders JH, et al. Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines. Radiother Oncol. 2005;76:194–199
  33. Trotter MJ, Chaplin DJ, Durand RE, Olive PL. The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int J Radiat Oncol Biol Phys. 1989;16:931–934
  34. Warters RL, Adamson PJ, Pond CD, Leachman SA. Melanoma cells express elevated levels of phosphorylated histone H2AX foci. J Invest Dermatol. 2005;124:807–817
  35. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000;60:7075–7083
  36. Yu T, MacPhail SH, Banath JP, Klokov D, Olive PL. Endogenous expression of phosphorylated histone H2AX in tumors in relation to DNA double-strand breaks and genomic instability. DNA Repair (Amst). 2006;5:935–946

PII: S0167-8140(09)00589-1

doi: 10.1016/j.radonc.2009.10.009

Radiotherapy & Oncology
Volume 94, Issue 1 , Pages 82-89 , January 2010

Article Tools

* Image Usage & Resolution